Amgen Inc./UCB SA's investigational therapy for osteoporosis Evenity (romosozumab) could still bring in sales of more than half a billion dollars despite delays to market and concerns over its adverse event profile, say analysts as the product received a Complete Response Letter from the US FDA.
Hopes for a swift approval for the first-in-class sclerostin inhibitor died when a cardiovascular safety signal overshadowed positive efficacy data...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?